Afinitor

Type: Product
Name: Afinitor
First reported 5 hours ago - Updated 1 hour ago - 1 reports

Novartis net profit jumps 24% to almost $3B

Novartis' ( NVS ) Q1 net profit leapt 24% to $2.97B and beat consensus of $2.7B, boosted by new drugs such as cancer treatment Afinitor and multiple sclerosis pill Gilenya. Sales in emerging markets, particularly China, also helped lift Novartis' earnings. ... [Published Seeking Alpha - 5 hours ago]
First reported 5 hours ago - Updated 2 hours ago - 1 reports

Novartis First-Quarter Profit Rises - WSJ.com

ZURICH—Novartis AG said sales of newly-launched drugs helped push first-quarter net profit about 23% higher, a strong performance that comes as the pharmaceutical giant embarks on a major overhaul of its sprawling product portfolio. Cancer treatment Afinitor ... [Published DailyMe.Com - 5 hours ago]
First reported 3 hours ago - Updated 2 hours ago - 1 reports

Novartis' Q1 net income rises on sale of blood transfusion diagnostics unit

Novartis said Thursday that net income for the first quarter jumped 24 percent to just under $3 billion as the company recorded a $900 million gain from the divestment of its blood transfusion diagnostics unit to Grifols for $1.7 billion. Overall revenue ... [Published FirstWord Pharma - 3 hours ago]
First reported 2 hours ago - Updated 2 hours ago - 1 reports

UPDATE 2-Novartis sales miss forecast as readies overhaul

* Q1 sales $14 bln vs $14.25 bln forecast* Q1 net profit $2.97 bln vs $2.7 bln in Reuters poll* To consolidate back room functions to boost profitability* Confirms full-year outlook(Adds analyst, shares, details on Afinitor)ZURICH, April 24 (Reuters) ... [Published CNBC - 2 hours ago]
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff

SummaryRX-21101, a nanopolymer formulation of popular cancer drug Taxotere, showed encouraging results in mice models that suggest more specific tumor targeting, less toxicity, and better survival rates. Lead drug Archexin is ready for Phase IIa trials ... [Published Seeking Alpha - Apr 21 2014]
Entities: Taxotere, Patent, Big Pharma
First reported Apr 20 2014 - Updated Apr 20 2014 - 1 reports

Cancer’s ‘miracle patients’ studied for disease clues

BOSTON – The history of oncology is rife with reports of patients with advanced cancer who staged miraculous recoveries. Now scientists are starting to use sophisticated DNA sequencing technology to determine if these “exceptional responders” carry gene ... [Published Japan Times - Apr 20 2014]
Entities: Mutation, Cancer, Afinitor, Tumor
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

ONE WOMANS FIGHT WITH BREAST CANCER

for postmenopausal women with advanced HR+/HER2 negative breast cancer in combination with exemestane (a commonly used option) after failure of treatment with letrozole or anastrozole, offering another option for patients.“My diagnosis helped me realize ... [Published Montana News Association - Apr 18 2014]
First reported Apr 09 2014 - Updated Apr 10 2014 - 1 reports

The CementBloc Named Finalists in Three Categories for the 2014 DTC National

Advertising Awards04/09 13:33 CDT Advertising Awards NEW YORK, April 9, 2014NEW YORK, April 9, 2014 /PRNewswire/ -- The CementBloc, a leading healthwellness communications company headquartered in New York City, has been named a finalist in three ... [Published Finwin - Apr 09 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Bionomics announces encouraging results from Phase II renal cancer trial

Bionomics Limited, a biopharmaceutical company, has announced results from the Phase II DISRUPTOR-1 trial of BNC105 in patients with metastatic renal cancer. "The DISRUPTOR-1 trial has been the first of its kind in testing the combination of an mTOR inhibitor ... [Published Individual.com - Mar 31 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Breast cancer drug therapy "set to become more dynamic"

The landscape for breast cancer therapies is set to become more dynamic, as newer targeted agents and drug combinations launch over the next few years, according to new research from Decision Resources. A US survey conducted for the study also finds that, ... [Published Pharma Times - Mar 31 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast cancer and, according to the majority of oncologists surveyed by Decision Resources, the escalating overall cost of drug treatment for breast cancer ... [Published Pharma Letter - Mar 28 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 3 reports

AfinitorAromasin combo disappoints in breast cancer trial

A combination of Novartis' Afinitor and Pfizer's Aromasin failed to reach statistical significance in a trial’s secondary endpoint of overall survival. Eagerly-awaited results from ... ... [Published Big News Network - Mar 25 2014]

Quotes

"The transformational deals announced on Tuesday position the company for future success based on our sharpened focus, innovation power and financial strength" he said
Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Novartis delivered a solid quarter, with all divisions contributing to growth. We made progress in innovation, including EU and US approval of Xolair [omalizumab] in chronic spontaneous urticaria and significant milestones for Bexsero. The transformational deals announced on Tuesday position the company for future success based on our sharpened focus, innovation power and financial strength."
"The slight disappointment was a 2 percent sales miss in pharma" said Berenberg analyst Alistair Campbell
"We had a solid first quarter," CEO Joe Jimenez remarked, adding "all the divisions showed some nice sales growth. We’re off to a good start in the fiscal year." Bernstein & Co. analyst Tim Anderson said the results were "largely in line" with consensus estimates

More Content

All (69) | News (68) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Pharma giant Novartis sees net profit jump [Published MSN New Zealand - 1 hour ago]
Novartis 1st-qtr net profit flat, sales shy of ... [Published Pharma Letter - 2 hours ago]
UPDATE 2-Novartis sales miss forecast as readie... [Published CNBC - 2 hours ago]
Novartis' Q1 net income rises on sale of blood ... [Published FirstWord Pharma - 3 hours ago]
Novartis net profit jumps 24% to almost $3B [Published Seeking Alpha - 5 hours ago]
Novartis First-Quarter Profit Rises - WSJ.com [Published DailyMe.Com - 5 hours ago]
UPDATE 1-Sale of blood transfusion test unit bo... [Published Reuters - 5 hours ago]
Novartis Plans Acquisition of GSK’s Oncology Pr... [Published OncLive - Apr 23 2014]
$16B deal for GlaxoSmithKline oncology meds tur... [Published FiercePharma - Apr 22 2014]
Success Of Rexahn's Nano-Sized Taxotere Can Hel... [Published Seeking Alpha - Apr 21 2014]
Cancer’s ‘miracle patients’ studied for disease... [Published Japan Times - Apr 20 2014]
ONE WOMANS FIGHT WITH BREAST CANCER [Published Montana News Association - Apr 18 2014]
A Conversation With David I. Quinn, MBBS, PhD, ... [Published The ASCO Post - Apr 15 2014]
Don’t underestimate the potential of new products [Published pharmaphorum - Apr 14 2014]
Novartis overtakes Pfizer as top drug company [Published Crains Detroit Business - Apr 14 2014]
Bladder Cancer Patient With Rare Genetic Mutati... [Published The ASCO Post - Apr 12 2014]
National Cancer Institute investigating trial o... [Published FierceBiotech - Apr 11 2014]
Asia Pacific Solid Tumors Market 2013-2019 [Published Individual.com - Apr 11 2014]
Rexahn Pharmaceuticals : Reports Fourth Quarter... [Published 4 Traders - Apr 10 2014]
The CementBloc Named Finalists in Three Categor... [Published Finwin - Apr 09 2014]
Cancer analysis tools circumvent biopsies [Published Boston Globe - Apr 08 2014]
Cancer Analysis Tools Circumvent Biopsies [Published Columbus - Apr 08 2014]
Pfizer Inc's Palbociclib Delivers the Goods [Published Motley Fool Discussion Boards - Apr 07 2014]
Three New Personalized Medicines for Breast Can... [Published PRWeb - Apr 03 2014]
Everolimus benefited bladder cancer patient wit... [Published Orthopedics Today - Apr 01 2014]
Novartis announces good heart drug results [Published Medical Marketing And Media - Mar 31 2014]
Bionomics announces encouraging results from Ph... [Published Individual.com - Mar 31 2014]
Breast cancer drug therapy "set to become more ... [Published Pharma Times - Mar 31 2014]
Factors driving oncologists’ prescribing decisi... [Published Pharma Letter - Mar 28 2014]
Patent expiration, stagnant R&D spend seriously... [Published PharmaBiz - Mar 28 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Here’s Why Novartis’ Japanese Unit Was Raided [Published Wall St. Cheat Sheet - Feb 23 2014]
Last month, the Japanese Health Ministry filed a complaint against Switzerland-based drugmaker Novartis AG’s ( NYSE:NVS ) Japan unit after the company used allegedly false data to advertise for its best-selling blood pressure drug, Diovan , the ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.